Boundless Bio, Inc.
NASDAQ:BOLDBiotechnology
Healthcare
$2.38 +85.71%
+$1.20 today
- Market cap
- $56.20M
- Beta
- 0.97
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$2.50
52W Low $0.96High $2.75
Volume 0.13M
Average 0.22M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$63.55M
FY 2025 · Annual
Net Income
-$58.20M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.09M | 1.25M |
| Gross Profit | 0 | 0 | 0 | (1.09M) | (1.25M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 19.28M | 37.16M | 42.64M | 55.27M | 44.85M |
| Selling, General & Admin | 6.02M | 9.31M | 12.16M | 18M | 18.71M |
| Operating Expenses | 25.3M | 46.47M | 54.8M | 72.18M | 62.3M |
| Depreciation & Amortization | 682K | 942K | 957K | 1.09M | 1.25M |
| EBITDA | (24.53M) | (44.96M) | (48.48M) | (64.28M) | (56.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (25.3M) | (46.47M) | (54.8M) | (73.27M) | (63.55M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 96K | 668K | 5.28M | 7.89M | 5.36M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 91K | 568K | 5.36M | 7.9M | 5.36M |
| Income Before Tax | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (25.21M) | (45.9M) | (49.43M) | (65.36M) | (58.2M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.13) | (2.06) | (2.22) | (3.85) | (2.60) |
| EPS (Diluted) | (1.13) | (2.06) | (2.22) | (3.85) | (2.60) |
| 22.24M | 22.24M | 22.24M | 16.98M | 22.36M | |
| 22.24M | 22.24M | 22.24M | 16.98M | 22.36M |
BOLD Earnings Waterfall · TTM
NASDAQ:BOLD · Revenue to Net Income
Key Ratios
EPS$-2.50
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.5
P/S Ratio0.0
Analysis
$0 of revenue converted into -$56.0M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.50, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 5, 2026 | |
| EFFECT | EFFECT filing | Nov 3, 2026 | |
| 424B3 | 424B3 filing | Nov 3, 2026 |
How much revenue does BOLD generate?
Boundless Bio, Inc. (BOLD) reported $0.00 of revenue in fiscal 2025.
Is BOLD profitable?
Boundless Bio, Inc. (BOLD) reported -$58.20M of net income.
Continue the stock analysis
Jump to another research area for this company.